Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) announced on October 29, 2025, the signing of a non-exclusive distribution and wholesale agreement with Phalanx, Comercializadora e Importadora de Componentes SA DE CV, a Mexico-based company. This agreement follows a non-binding Letter of Intent announced on June 24, 2025, and represents a mutual commitment to expand into the Mexican healthcare sector, specifically in barium-based contrast media.
Under the agreement, Phalanx will lead the registration of Voyageur’s barium contrast media products with Mexican health regulatory authorities and distribute them through its established network. Voyageur will support Phalanx in regulatory approval, market access, and commercialization. This partnership aims to establish Voyageur’s presence in Mexico’s medical imaging and contrast media markets, which are underserved but growing.
Phalanx is a pharmaceutical distributor with a strong footprint in Mexico and Latin American markets that recognize Canadian regulatory approvals. The company offers commercial intelligence, market entry strategies, and operational execution to ensure successful product launches and sustainable growth. Its expertise in regulatory compliance and supply chain management is expected to accelerate Voyageur’s market entry while minimizing risk.
Brent Willis, CEO of Voyageur, stated, “This agreement marks a significant step forward in our commercialization roadmap. It reflects our continued commitment to expanding global access to our innovative, cost-effective imaging solutions. Latin America is a critical market in our expansion plan, and this partnership lays the groundwork for long term growth.”
Sales of Voyageur’s barium sulfate contrast media products in Mexico and other Latin American countries will depend on local regulatory approvals. Phalanx will take the lead in preparing and submitting necessary filings, with support from Voyageur’s technical and regulatory team. This partnership aligns with Voyageur’s strategy to vertically integrate the barium and iodine contrast markets, aiming to become a key player by producing its own active pharmaceutical ingredients.
Voyageur owns a 100% interest in the Frances Creek Project, which boasts a rare high-grade mineral suitable for pharmaceutical barium sulfate, potentially replacing synthetic products with higher quality imaging agents. The company plans to transition into a high-margin domestic manufacturer of radiology drugs. More information is available at https://voyageurpharmaceuticals.ca.
This announcement contains forward-looking information, including statements about regulatory approvals, market expansion, and the potential of the Frances Creek Project. Actual results may differ materially due to risks and uncertainties outlined in Voyageur’s disclosure documents on SEDAR+ at www.sedarplus.ca.
